Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBARQ-CSU1 barzolvolimab phase 3 study in chronic spontaneous urticaria
NL-OMON59095Phase 3Active, not recruiting
- Sponsor
- Celldex Therapeutics
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic idiopathic urticaria (CIU) comparing barzolvolimab with placebo (2 arms). Primary endpoint: Mean change from baseline in UAS7 at Week 12. Started Apr 2025; status: active, not recruiting.
02
Drugs
barzolvolimab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on NL-OMON59095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59095.